Drug Profile
Research programme: tuberculosis therapeutics - TB Drug Accelerator
Latest Information Update: 20 Oct 2022
Price :
$50
*
At a glance
- Originator TB Drug Accelerator
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Tuberculosis
Most Recent Events
- 18 Oct 2022 Early research in Tuberculosis is ongoing in USA (Unspecified route)
- 28 Jul 2018 No recent reports of development identified for research development in Tuberculosis in USA
- 30 Apr 2012 TB Drug Accelerator partnership formed by seven pharmaceutical companies and four research institutions working with the Bill & Melinda Gates Foundation